Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy

Inclusion Criteria: * Male or female \> 18 years * Histologically confirmed solid tumor. * Subjects who have not received chemotherapy and / or radiotherapy in the last 3 months. * Subject to initiate a chemotherapy (ie, cycle 1, day 1) * The chemotherapy regimen should have an inherent risk of febrile neutropenia of 10-20%. * Planning a minimum of 3 cycles chemotherapy. * Adequate bone marrow reserve defined by: leukocytes ≥ 3,000 / mm3, platelets ≥ 100.000/mm3; neutrophils ≥ 1,500 / mm3. * Adequate hepatic and renal function, defined by: bilirubin \<1.5 times the normal value, ALT and AST \<3 times the normal range (both can be elevated up to 5 times the normal value in patients with known liver metastases); creatinine \<1.5 times upper normal value * ECOG ≤ 2. * Informed consent Exclusion Criteria: * Patients under treatment with an investigational treatment. * Active infection in the last 72 h before starting chemotherapy. * Indication of chemotherapy dose intensity or chemotherapy included in the risk rating of febrile neutropenia \<10% or \>20%. * Patients with concomitant chemoradiotherapy. * Patients being treated with biological drugs in monotherapy. * Any other condition causing neutropenia. * History of bone marrow transplant or stem cells.